Biomarker Testing for Non–Small Cell Lung Cancer in Community Practices Operated by an Academic Cancer Center
Most patients, especially those with nonsquamous NSCLC, treated at DFCI regional sites received guideline-concordant biomarker testing. Still, testing for rare biomarkers with recently approved targeted therapies lagged testing rates for long-established biomarkers, demonstrating the importance of rapid diffusion of novel biomarker testing into practice.
Authors
- L. Roby
- Thomas J. Roberts (ORCID: https://orcid.org/0000-0003-0709-2270)
- Bruce E. Johnson (ORCID: https://orcid.org/0000-0002-5252-3677)
- Kenneth L. Kehl (ORCID: https://orcid.org/0000-0001-5339-9797)
- Latrice Landry (ORCID: https://orcid.org/0000-0001-7499-3007)
- Christopher S. Lathan (ORCID: https://orcid.org/0000-0003-4549-3040)
- Paul Morgan (ORCID: https://orcid.org/0000-0003-1439-9545)
- Karim Farhat
- Chaimaa Hossaini
- Reem Sulieman
Institutions
- Harvard University (US)
- Dana-Farber Cancer Institute (US)
Publication Details
- Journal
- JCO Oncology Practice
- Published
- 2025-11-10
- DOI
- https://doi.org/10.1200/op-25-00280
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00